Descriptive only
Pancreatic cancer
Overweight or obesity without diabetes (adults)
longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)
2
Randomized trials
3
Treatments
631
Participants
0
Events
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 2 trials. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagOutcome assessment, definition: confounded with design: not stated 1, serious adverse events 1
- NoteOutcome assessment, time point: selected time points span 16.1 to 76 weeks
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02717858 | 16.1 | safety | serious adverse events | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2016 | age 18 to 64, BMI 27 or more, no diabetes, no gallbladder disease |
| SURMOUNT-3 | 76 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | age 18 or older; BMI 30 or more, or 27 or more with comorbidity; no diabetes; at least 5 percent loss in lead in |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT02717858 | A1 | LIRA_SC_3p0MG_QD | 16.1 | arm, events | 0 / 26 | R0024932:Results | |||
| NCT02717858 | A2 | PLACEBO | 16.1 | arm, events | 0 / 26 | R0024932:Results | |||
| SURMOUNT-3 | A1 | TIRZ_SC_MTD_QW | 76 | arm, events | 0 / 287 | R0007405:Results | |||
| SURMOUNT-3 | A2 | PLACEBO | 76 | arm, events | 0 / 292 | R0007405:Results |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.